2024
|
Molecular Manipulation to Enhance Anti-Myeloma Response
|
5I01BX001584-10
|
|
2024
|
Core 1: Administrative Core
|
5P01CA155258-12-8234
|
|
2024
|
Project 4: Targeting genomic instability and evolution in myeloma
|
5P01CA155258-12-8233
|
|
2024
|
Integrative Oncogenomics of Multiple Myeloma
|
5P01CA155258-12
|
|
2023
|
Molecular Manipulation to Enhance Anti-Myeloma Response
|
2I01BX001584-09
|
|
2023
|
Integrative Oncogenomics of Multiple Myeloma
|
2P01CA155258-11
|
|
2023
|
Core 1: Administrative Core
|
2P01CA155258-11-8234
|
|
2023
|
Project 4: Targeting genomic instability and evolution in myeloma
|
2P01CA155258-11-8233
|
|
2023
|
SPORE in Multiple Myeloma
|
5P50CA100707-20
|
|
2023
|
Targeting AP Nuclease, a Mediator of Genomic Instability in MM
|
5P50CA100707-20-8567
|
|
2023
|
Tissue Banking Core
|
5P50CA100707-20-8564
|
|
2022
|
Targeting AP Nuclease, a Mediator of Genomic Instability in MM
|
5P50CA100707-19-8567
|
|
2022
|
SPORE in Multiple Myeloma
|
5P50CA100707-19
|
|
2022
|
Tissue Banking Core
|
5P50CA100707-19-8564
|
|
2021
|
Molecular Manipulation to Enhance Anti-Myeloma Response
|
5I01BX001584-08
|
40
|
2021
|
Integrative Oncogenomics of Multiple Myeloma
|
5P01CA155258-10
|
229
|
2021
|
Project 4. Targeting genomic instability and evolution in myeloma
|
5P01CA155258-10-5947
|
229
|
2021
|
Core 1: Administrative and Communication Core
|
5P01CA155258-10-5939
|
229
|
2021
|
Targeting AP Nuclease, a Mediator of Genomic Instability in MM
|
5P50CA100707-18-8567
|
422
|
2021
|
Tissue Banking Core
|
5P50CA100707-18-8564
|
422
|
2021
|
SPORE in Multiple Myeloma
|
5P50CA100707-18
|
422
|
2020
|
Molecular Manipulation to Enhance Anti-Myeloma Response
|
5I01BX001584-07
|
40
|
2020
|
Project 4. Targeting genomic instability and evolution in myeloma
|
5P01CA155258-09-5947
|
229
|
2020
|
Core 1: Administrative and Communication Core
|
5P01CA155258-09-5939
|
229
|
2020
|
Integrative Oncogenomics of Multiple Myeloma
|
5P01CA155258-09
|
229
|
2020
|
SPORE in Multiple Myeloma
|
5P50CA100707-17
|
422
|
2020
|
Targeting AP Nuclease, a Mediator of Genomic Instability in MM
|
5P50CA100707-17-8567
|
422
|
2020
|
Tissue Banking Core
|
5P50CA100707-17-8564
|
422
|
2019
|
ShEEP request for next generation sequencing system
|
1IS1BX005034-01
|
|
2019
|
Molecular Manipulation to Enhance Anti-Myeloma Response
|
5I01BX001584-06
|
40
|
2019
|
Integrative Oncogenomics of Multiple Myeloma
|
5P01CA155258-08
|
229
|
2019
|
SPORE in Multiple Myeloma
|
2P50CA100707-16A1
|
422
|
2019
|
Tissue Banking Core
|
2P50CA100707-16A1-8564
|
422
|
2019
|
Targeting AP Nuclease, a Mediator of Genomic Instability in MM
|
2P50CA100707-16A1-8567
|
422
|
2019
|
Project 4. Targeting genomic instability and evolution in myeloma
|
5P01CA155258-08-5947
|
229
|
2019
|
Core 1: Administrative and Communication Core
|
5P01CA155258-08-5939
|
229
|
2018
|
Molecular Manipulation to Enhance Anti-Myeloma Response
|
2I01BX001584-05A2
|
40
|
2018
|
Integrative Oncogenomics of Multiple Myeloma
|
5P01CA155258-07
|
229
|
2018
|
Integrative Oncogenomics of Multiple Myeloma (1 of 2)
|
3P01CA155258-07S1
|
229
|
2018
|
Integrative Oncogenomics of Multiple Myeloma (2 of 2)
|
3P01CA155258-07S2
|
229
|
2018
|
Project 4. Targeting genomic instability and evolution in myeloma
|
3P01CA155258-07S1-5947
|
229
|
2018
|
Project 4. Targeting genomic instability and evolution in myeloma
|
3P01CA155258-07S2-5947
|
229
|
2018
|
Core 1: Administrative and Communication Core
|
3P01CA155258-07S1-5939
|
229
|
2018
|
Core 1: Administrative and Communication Core
|
3P01CA155258-07S2-5939
|
229
|
2018
|
Project 4. Targeting genomic instability and evolution in myeloma
|
5P01CA155258-07-5947
|
229
|
2018
|
Core 1: Administrative and Communication Core
|
5P01CA155258-07-5939
|
229
|
2017
|
ShEEP Request for BD FACSAria Fusion Cell Sorting Flow Cytometer
|
1IS1BX003970-01
|
|
2017
|
Integrative Oncogenomics of Multiple Myeloma
|
2P01CA155258-06
|
229
|
2017
|
Tissue Banking Core
|
5P50CA100707-15-6225
|
422
|
2017
|
Targeting Genomic Instability in Multiple Myeloma
|
5P50CA100707-15-6220
|
422
|
2017
|
Project 4. Targeting genomic instability and evolution in myeloma
|
2P01CA155258-06-5947
|
229
|
2017
|
Core 1: Administrative and Communication Core
|
2P01CA155258-06-5939
|
229
|
2016
|
MOLECULAR MANIPULATION TO ENHANCE ANTI-MYELOMA RESPONSE
|
5I01BX001584-04
|
40
|
2016
|
Tissue Banking Core
|
4P50CA100707-14-6225
|
422
|
2016
|
Targeting Genomic Instability in Multiple Myeloma
|
4P50CA100707-14-6220
|
422
|
2015
|
MOLECULAR MANIPULATION TO ENHANCE ANTI-MYELOMA RESPONSE
|
5I01BX001584-03
|
40
|
2015
|
Integrative Oncogenomics of Multiple Myeloma
|
5P01CA155258-05
|
229
|
2015
|
Targeting Genomic Instability in Multiple Myeloma
|
5P50CA100707-13-6220
|
422
|
2015
|
Tissue Banking Core
|
5P50CA100707-13-6225
|
422
|
2015
|
Administrative and Communication Core
|
5P01CA155258-05-6142
|
229
|
2015
|
Targeting Genomic Instability and Evolution in Myeloma
|
5P01CA155258-05-6141
|
229
|
2014
|
MOLECULAR MANIPULATION TO ENHANCE ANTI-MYELOMA RESPONSE
|
5I01BX001584-02
|
40
|
2014
|
Integrative Oncogenomics of Multiple Myeloma
|
5P01CA155258-04
|
229
|
2014
|
Innate and Adaptive Anti-Myeloma Immunity
|
5P01CA078378-15-7238
|
276
|
2014
|
Targeting Genomic Instability and Evolution in Myeloma
|
5P01CA155258-04-6141
|
229
|
2014
|
Administrative and Communication Core
|
5P01CA155258-04-6142
|
229
|
2014
|
Targeting Genomic Instability in Multiple Myeloma
|
5P50CA100707-12-6220
|
422
|
2014
|
Tissue Banking Core
|
5P50CA100707-12-6225
|
422
|
2013
|
MOLECULAR MANIPULATION TO ENHANCE ANTI-MYELOMA RESPONSE
|
1I01BX001584-01A1
|
40
|
2013
|
Integrative Oncogenomics of Multiple Myeloma
|
5P01CA155258-03
|
229
|
2013
|
Tissue Banking Core
|
2P50CA100707-11A1-6225
|
422
|
2013
|
Targeting Genomic Instability in Multiple Myeloma
|
2P50CA100707-11A1-6220
|
422
|
2013
|
Administrative and Communication Core
|
5P01CA155258-03-6142
|
229
|
2013
|
Targeting Genomic Instability and Evolution in Myeloma
|
5P01CA155258-03-6141
|
229
|
2013
|
Innate and Adaptive Anti-Myeloma Immunity
|
5P01CA078378-14-7238
|
276
|
2012
|
Administrative and Communication Core
|
5P01CA155258-02-6142
|
229
|
2012
|
Targeting Genomic Instability and Evolution in Myeloma
|
5P01CA155258-02-6141
|
229
|
2012
|
Integrative Oncogenomics of Multiple Myeloma
|
5P01CA155258-02
|
229
|
2012
|
Homologous Recombination Mediates Genomic Instability and Progression in Myeloma
|
5R01CA124929-05
|
30
|
2012
|
P-2: Targeting telomerase expansion mechanism in MM
|
5P50CA100707-10-2
|
422
|
2012
|
Innate and Adaptive Anti-Myeloma Immunity
|
5P01CA078378-13-7238
|
276
|
2011
|
Administrative and Communication Core
|
1P01CA155258-01-5512
|
229
|
2011
|
Targeting Genomic Instability and Evolution in Myeloma
|
1P01CA155258-01-5511
|
229
|
2011
|
Integrative Oncogenomics of Multiple Myeloma
|
1P01CA155258-01
|
229
|
2011
|
Innate and Adaptive Anti-Myeloma Immunity
|
5P01CA078378-12-7238
|
276
|
2011
|
Homologous Recombination Mediates Genomic Instability and Progression in Myeloma
|
5R01CA124929-04
|
30
|
2011
|
P-2: Targeting telomerase expansion mechanism in MM
|
5P50CA100707-09-2
|
422
|
2010
|
Innate and Adaptive Anti-Myeloma Immunity
|
2P01CA078378-11A2-7238
|
276
|
2010
|
Homologous Recombination Mediates Genomic Instability and Progression in Myeloma
|
5R01CA124929-03
|
30
|
2010
|
P-2: Targeting telomerase expansion mechanism in MM
|
5P50CA100707-08-2
|
422
|
2009
|
Homologous Recombination Mediates Genomic Instability and Progression in Myeloma
|
5R01CA124929-02
|
30
|
2009
|
P-2: Targeting telomerase expansion mechanism in MM
|
5P50CA100707-07-2
|
422
|
2008
|
P-2: Targeting telomerase expansion mechanism in MM
|
2P50CA100707-06-2
|
422
|
2008
|
Homologous Recombination Mediates Genomic Instability and Progression in Myeloma
|
1R01CA124929-01A2
|
30
|
2000
|
DEVELOPMENTAL THERAPEUTICS
|
3P01CA055819-05A1S1-6
|
294
|
1998
|
GRAFT VS MYELOMA EFFECT OF TK TRANSDUCED LYMPHOCYTES
|
3R21CA071092-02S1
|
10
|
1996
|
GRAFT VS MYELOMA EFFECT OF TK TRANSDUCED LYMPHOCYTES
|
1R21CA071092-01
|
10
|
1996
|
GRAFT VS MYELOMA EFFECT OF TK-TRANSDUCED LYMPHOCYTES
|
5R01HL055695-02
|
8
|
1995
|
GRAFT VS MYELOMA EFFECT OF TK-TRANSDUCED LYMPHOCYTES
|
1R01HL055695-01
|
8
|